Literature DB >> 711224

Histologic changes in Paget's disease treated with calcitonin.

V L Fornasier, K Stapleton, C C Williams.   

Abstract

In recent years the use of calcitonin in the medical treatment of Paget's disease of bone has been gaining in popularity. Seventeen patients on long term calcitonin therapy showed objective morphologic evidence of improvement in the quality of bone matrix deposition, in the trabecular organization, and in the parameters used to evaluate the rates of bone turnover. The usefulness of bone biopsy and fine detail radiography of the biopsy core in evaluating the progress of disease and the effects of therapy is discussed. It is concluded that the longer the period of therapy and follow-up, the higher the proportion of patients showing histologic evidence of improvement.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 711224     DOI: 10.1016/s0046-8177(78)80030-6

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  5 in total

Review 1.  Salmon calcitonin: a review of current and future therapeutic indications.

Authors:  C H Chesnut; M Azria; S Silverman; M Engelhardt; M Olson; L Mindeholm
Journal:  Osteoporos Int       Date:  2007-12-11       Impact factor: 4.507

Review 2.  The contribution of Sir James Paget (1814-1894) to the study of rheumatic disease.

Authors:  W Buchanan
Journal:  Clin Rheumatol       Date:  1996-09       Impact factor: 2.980

Review 3.  Treating Paget's disease.

Authors:  D A Heath
Journal:  Br Med J (Clin Res Ed)       Date:  1987-04-25

4.  Bone turnover in Paget's disease: biochemical and kinetic measurements during salmon calcitonin therapy.

Authors:  D J Hosking; W Vennart; L B Huddlestone
Journal:  Calcif Tissue Int       Date:  1981       Impact factor: 4.333

Review 5.  Management of osteoporosis and Paget's disease. An appraisal of the risks and benefits of drug treatment.

Authors:  C Gennari; R Nuti; D Agnusdei; A Camporeale; G Martini
Journal:  Drug Saf       Date:  1994-09       Impact factor: 5.606

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.